XGEVA® is indicated for: Prevention of skeletal related events* in adults with bone metastases from solid tumours, and treatment of adult and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. *Skeletal-related events (SREs): pathological fracture, radiation to bone, spinal cord compression or surgery to bone.

For further information please refer to the full prescribing information as approved by Israeli MOH

License Holder: Amgen Europe B.V., Israel Branch